Live Chat ×
Skip to main content

Managing Elevated LDL-C: New Guidelines and New Agents


A CME/MOC/MIPS Activity 

TO REGISTER:
Click here to complete your registration.


If you will be watching the webinar in a group setting, please note all group participants will need to register individually in order to complete the post-test and evaluation to receive credit.

DATES AND TIMES
Thursday, January 28, 2021
6:15 - 7:15 PM ET (5:15 - 6:15 PM CT / 3:15 - 4:15 PM PT)
Hosted by: Louisiana Chapter of the American College of Cardiology

Thursday, February 4, 2021
8:30 - 9:30 PM ET (7:30 - 8:30 PM CT / 5:30 - 6:30 PM PT)
Hosted by: Arizona, California, Colorado and Washington State Chapters of the American College of Cardiology

Tuesday, February 9, 2021
7:00 - 8:00 PM ET (6:00 - 7:00 PM CT /4:00 - 5:00 PM PT)
Hosted by: Ohio Chapter of the American College of Cardiology

Thursday, March 18, 2021
7:00 - 8:00 PM ET (6:00 - 7:00 PM CT /4:00 - 5:00 PM PT)
Hosted by: Indiana Chapter of the American College of Cardiology

AGENDA
Welcome and Introduction
Current Evidence-Based Guidelines for the Management of Elevated LDL-C
Beyond Statins: Role of Non-statin Agents in Managing Elevated LDL-C
Q&A Session and Activity Roundup

PROGRAM DESCRIPTION
Elevated low-density lipoprotein cholesterol (LDL-C) levels are a major contributor to arteriosclerotic cardiovascular disease (ASCVD). In 2018, the AHA and ACC jointly published an updated guideline on blood cholesterol management, providing new guidance on primary and secondary ASCVD prevention including LDL-C threshold levels for treatment and outlining the role of more recently approved agents. In addition, the European Society of Cardiology (ESC)/European Atherosclerosis Society (EAS) published guidelines in 2019 that recommended lower LDL-C goal levels, a new definition of high-risk patients that expanded the number of patients in this group, and recommends more aggressive use of non-statin agents compared to the 2018 ACC/AHA guidelines.

Unfortunately, mean LDL-C levels in the US continue to rise. To achieve the AHA’s 2030 impact goal, the new guidelines and new agents will need to be incorporated into clinical practice. This educational activity, “Managing Elevated LDL-C: New Guidelines and New Agents” will provide cardiologists with information about the new guidelines, expert opinion on the role of agents recently approved by the FDA after the guideline publication, and a review of results from trials of agents in late stage development.

STEERING COMMITTEE
Seth Martin, MD
Associate Professor of Medicine - Cardiology
Johns Hopkins University School of Medicine
Director, Advanced Lipid Disorders Program
Ciccarone Center for the Prevention of Cardiovascular Disease
Baltimore, MD


Erin D. Michos, MD, MHS, FAHA, FACC, FASE, FASPC
Associate Professor of Medicine and Epidemiology
Director of Women’s Cardiovascular Health
Associate Director of Preventive Cardiology
Ciccarone Center for the Prevention of Heart Disease
Division of Cardiology, Johns Hopkins School of Medicine
Baltimore, MD

TARGET AUDIENCE

This activity is intended for cardiologists and other health care professionals who manage patients with dyslipidemia.

EDUCATIONAL OBJECTIVES
This activity is designed to address ACGME and NAM competencies, including delivering patient-centered care and practicing evidence-based medicine.

At the conclusion of an activity, participants should be able to:
  • Provide individualized primary prevention plans for patients with elevated LDL-C levels using the 2018 cholesterol guidelines
  • Develop individualized secondary prevention strategies for patients with elevated LDL-C levels based on recommendations in the 2018 cholesterol guidelines
  • Employ adjunctive non-statin agents to intensify LDL-C management when statins alone do not achieve 2018 blood cholesterol guideline goals
  • Evaluate the most current efficacy and safety data for non-statin agents approved for managing elevated LDL-C

ACCREDITATION
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of Boston University School of Medicine and Rockpointe. Boston University School of Medicine is accredited by the ACCME to provide continuing medical education for physicians.

CREDIT DESIGNATION
Boston University School of Medicine designates this live activity for a maximum of 1.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

ABIM MOC DESIGNATION STATEMENT

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 1.0 Medical Knowledge MOC points in the American Board of Internal Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

To receive CME credit and/or MOC points, you MUST pass the post-test and complete the evaluation. For ABIM MOC points, your information will be shared with the ABIM through BUSM’s ACCME Program and Activity Reporting System (PARS). Please allow 6-8 weeks for your MOC points to appear on your ABIM records.

MIPS CREDIT DESIGNATION
Completion of this accredited CME activity meets the expectations of an Accredited Safety or Quality Improvement Program (IA_PSPA_28) for the Merit-based Incentive Payment Program (MIPS).

DISCLAIMER

THESE MATERIALS AND ALL OTHER MATERIALS PROVIDED IN CONJUNCTION WITH CONTINUING MEDICAL EDUCATION ACTIVITIES ARE INTENDED SOLELY FOR PURPOSES OF SUPPLEMENTING CONTINUING MEDICAL EDUCATION PROGRAMS FOR QUALIFIED HEALTH CARE PROFESSIONALS. ANYONE USING THE MATERIALS ASSUMES FULL RESPONSIBILITY AND ALL RISK FOR THEIR APPROPRIATE USE. TRUSTEES OF BOSTON UNIVERSITY MAKES NO WARRANTIES OR REPRESENTATIONS WHATSOEVER REGARDING THE ACCURACY, COMPLETENESS, CURRENTNESS, NONINFRINGEMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE OF THE MATERIALS. IN NO EVENT WILL TRUSTEES OF BOSTON UNIVERSITY BE LIABLE TO ANYONE FOR ANY DECISION MADE OR ACTION TAKE IN RELIANCE ON THE MATERIALS. IN NO EVENT SHOULD THE INFORMATION IN THE MATERIALS BE USED AS A SUBSTITUTE FOR PROFESSIONAL CARE.

DISCLOSURE STATEMENT
This educational activity has been produced in adherence with the policies and guidelines, including the Standards for Commercial Support, set forth to providers by the Accreditation Council for Continuing Medical Education (ACCME) and all other professional organizations, as applicable, stating those activities where continuing education credits are awarded must be balanced, independent, objective, and scientifically rigorous.

Boston University School of Medicine asks all individuals, and their spouses/partners, involved in the development and presentation of Continuing Medical Education (CME) and Continuing Nursing Education (CNE) activities to disclose all relevant financial relationships with commercial interests. This information is disclosed to CME activity participants prior to the start of the educational activity. Boston University School of Medicine has procedures to resolve all conflicts of interest. In addition, faculty members are asked to disclose when any unapproved use of pharmaceuticals and devices is being discussed.

Disclosures will be made known to the participants prior to the start of the activity.

FDA DISCLOSURE
The contents of some CME/CE activities may contain discussions of non-approved or off-label uses of some agents mentioned. Please consult the prescribing information for full disclosure of a
pproved uses.

SYSTEM CHECK
To ensure your computer is compatible for the live event, please perform a system check by clicking on the link http://livewebcast.net/test or by typing it into your internet browser. Please perform the system check on the same computer you will use for the live event. If your computer is compatible, you will receive a confirmation message on your screen and hear audio. Otherwise, please contact the Help Desk to resolve any issues.

HARDWARE REQUIREMENTS
WINDOWS
  • 1.4 GHz Intel Pentium 4 or faster processor (or equivalent)
  • Windows 10, 8.1 (32-bit/64-bit), Windows 7 (32-bit/64-bit)
  • 512 MB of RAM (1 GB recommended)
  • Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
MAC OS
  • 1.83 GHz Intel Core Duo or faster processor
  • 512 MB RAM (1 GB recommended)
  • Mac OS X 10.12, 10.13 and 10.14
  • Mozilla Firefox, Apple Safari, Google Chrome
  • For HTML Client - Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
MOBILE
  • The Adobe Connect app for iOS and Android requires Adobe Connect Server version 8.2 or later
  • Some features may not be enabled in all Adobe Connect meetings if one is using an Adobe Connect Server older than version 9.4.2 (required for Custom pods)
  • Google Android 4.4 or later
  • Apple iOS: iOS 8.1.2 or later
SOFTWARE REQUIREMENTS
DSL/cable (wired connection recommended)

INSTRUCTIONS FOR PARTICIPANTS AND OBTAINING CME/MOC CREDIT
There is no fee for this activity. To receive credit, participants must register, view the live CME/MOC activity in its entirety, and then complete the post-test with a score of 75% or better and the evaluation. The estimated time for completion of this activity is 1 hour. To receive a certific
ate, participants must demonstrate mastery of the presented material via the post-test. Participants are allowed to take the post-test multiple times.

Jointly provided by Boston University School of Medicine and Rockpointe
   

This program is supported by educational funding provided by Amgen and Novartis Pharmaceuticals Corporation.

Rockpointe Privacy Policy